Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

Saved in:
Bibliographic Details
Title: Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
Authors: Halbert CL; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA., Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML
Source: Human gene therapy [Hum Gene Ther] 2006 Apr; Vol. 17 (4), pp. 440-7.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: M.A. Liebert Country of Publication: United States NLM ID: 9008950 Publication Model: Print Cited Medium: Print ISSN: 1043-0342 (Print) Linking ISSN: 10430342 NLM ISO Abbreviation: Hum Gene Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1043-0342
DOI:10.1089/hum.2006.17.440